"The safety results are supported with the findings from our pre-clinical data that DMT210 has a favorable safety profile, which remains extremely important to patients and dermatologists for dermal products," states Gerald Proehl, President and CEO of Dermata. "We are also very excited to see that DMT210 reduced erythema and lesion counts in only a 28-day study, giving us further confidence that we will see even greater reductions in our 90-day study."
With the completion of this study, Dermata plans to move into two Phase 2 studies in Acne Rosacea and Atopic Dermatitis, both expected to start later this year.
About Dermata: Dermata is a development-stage biotechnology company focused on making major advancements in the treatment of serious diseases treated by dermatologists. Dermata has a team of experienced individuals who are currently focused on progressing four programs for the treatment of acne rosacea, acne vulgaris, atopic dermatitis and ocular rosacea. To learn more about Dermata and its pipeline of treatments, please visit www.dermatarx.com.
Logo - http://photos.prnewswire.com/prnh/20160512/367116LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dermata-therapeutics-llc-announces-positive-top-line-results-from-their-phase-1-pharmacokinetic-study-of-dmt210-in-acne-rosacea-patients-300335381.html
SOURCE Dermata Therapeutics, LLC